EDUCATION

Medical School

  • American University of Beirut , 1995 , Beirut , Lebanon

Internship

  • American University of Beirut , 1996 , Beirut , Lebanon

Residency

  • American University of Beirut , 1998 , Beirut , Lebanon

Fellowship

  • Boston Children's Hospital , 2002 , Boston , MA

Residency

  • Boston Children's Hospital , 2004 , Boston , MA

CERTIFICATIONS

  • American Board of Allergy and Immunology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Biologics and Novel Therapies for Food Allergy. Immunol Allergy Clin North Am. 2021 May; 41(2):271-283. View abstract
  2. The microbial origins of food allergy. J Allergy Clin Immunol. 2021 Mar; 147(3):808-813. View abstract
  3. Regulatory T Cell-Derived TGF-ß1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. Immunity. 2020 Dec 15; 53(6):1331-1332. View abstract
  4. Regulatory T Cell-Derived TGF-ß1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. Immunity. 2020 12 15; 53(6):1202-1214.e6. View abstract
  5. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J Allergy Clin Immunol Pract. 2020 10; 8(9S):S16-S116. View abstract
  6. [Erratum to "Unusual bilateral eyelid and orbital involvement in Rosai-Dorfman disease (a comprehensive literature review and case report)" [J. Fr. Ophtalmol. 39 (2016) e221-e225]]. J Fr Ophtalmol. 2020 Sep; 43(7):687. View abstract
  7. Novel Therapies for Treatment of Food Allergy. Immunol Allergy Clin North Am. 2020 02; 40(1):175-186. View abstract
  8. Peanut Oral Immunotherapy: Is It Safer in Preschoolers than in Older Age Groups? J Allergy Clin Immunol Pract. 2019 Nov - Dec; 7(8):2768-2769. View abstract
  9. Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma. J Allergy Clin Immunol. 2020 03; 145(3):897-906. View abstract
  10. Author Correction: Microbiota therapy acts via a regulatory T cell MyD88/ROR?t pathway to suppress food allergy. Nat Med. 2019 Sep; 25(9):1458. View abstract
  11. Microbiota therapy acts via a regulatory T cell MyD88/ROR?t pathway to suppress food allergy. Nat Med. 2019 07; 25(7):1164-1174. View abstract
  12. Reply. J Allergy Clin Immunol Pract. 2019 04; 7(4):1376-1377. View abstract
  13. The emerging biologic therapies on food allergy. Ann Allergy Asthma Immunol. 2019 06; 122(6):556-558. View abstract
  14. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018 Nov 22; 379(21):1991-2001. View abstract
  15. Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. Ann Allergy Asthma Immunol. 2019 02; 122(2):213-215. View abstract
  16. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract. 2019 03; 7(3):1024-1031.e3. View abstract
  17. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract. 2019 02; 7(2):451-461.e7. View abstract
  18. Defective TLR9-driven STAT3 activation in B cells of patients with CVID. Clin Immunol. 2018 12; 197:40-44. View abstract
  19. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol. 2018 12; 121(6):722-728.e1. View abstract
  20. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018 07; 48(7):825-836. View abstract
  21. Food Allergy: What's on the Menu in 2018? J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):419-420. View abstract
  22. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. J Allergy Clin Immunol Pract. 2018 Sep - Oct; 6(5):1711-1716.e4. View abstract
  23. Current Status and Unanswered Questions for Food Allergy Treatments. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):377-382. View abstract
  24. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):476-485.e3. View abstract
  25. Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). J Allergy Clin Immunol. 2017 06; 139(6):2007-2010.e8. View abstract
  26. The role of the gut microbiota in food allergy. Curr Opin Pediatr. 2016 12; 28(6):748-753. View abstract
  27. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8. View abstract
  28. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. Curr Allergy Asthma Rep. 2016 Apr; 16(4):25. View abstract
  29. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015; 8(1):20. View abstract
  30. TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development. J Allergy Clin Immunol. 2015 Nov; 136(5):1315-25. View abstract
  31. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015 Mar 17; 42(3):512-23. View abstract
  32. Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014 Dec; 134(6):1310-1317.e6. View abstract
  33. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013 Dec; 132(6):1368-74. View abstract
  34. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest. 2013 Oct; 123(10):4283-93. View abstract
  35. [Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy]. J Fr Ophtalmol. 2013 Nov; 36(9):758-63. View abstract
  36. Administration of intravenous immunoglobulin to a patient with hypogammaglobulinemia and anti-IgA antibodies. J Allergy Clin Immunol Pract. 2013 Nov-Dec; 1(6):704. View abstract
  37. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol. 2012 Sep; 34(5):689-702. View abstract
  38. Reply. J Allergy Clin Immunol. 2012 Aug; 130(2):554. View abstract
  39. Intraoperative anaphylaxis induced by the gelatin component of thrombin-soaked gelfoam in a pediatric patient. Ann Allergy Asthma Immunol. 2012 Mar; 108(3):209-10. View abstract
  40. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012 Mar; 129(3):628-34. View abstract
  41. Reply. J Allergy Clin Immunol. 2011 Oct; 128(4):905. View abstract
  42. Reply. J Allergy Clin Immunol. 2011 Jul; 128(1):251-2. View abstract
  43. Association of anti-IgA antibodies with adverse reactions to ?-globulin infusion. J Allergy Clin Immunol. 2011 Jul; 128(1):228-230.e1. View abstract
  44. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol. 2011 Feb; 127(2):524-8. View abstract
  45. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007 Apr; 39(4):430-1. View abstract
  46. TACI mutation in common variable immunodeficiency and IgA deficiency. Curr Allergy Asthma Rep. 2006 Sep; 6(5):357-62. View abstract
  47. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug; 37(8):829-34. View abstract
  48. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell. 2002; 10(6):1269-81. View abstract
  49. Treatment-resistant infantile Evans syndrome. Pediatr Int. 2001 Oct; 43(5):502-4. View abstract
  50. Consequences of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor blockade during status epilepticus in the developing brain. Brain Res Dev Brain Res. 1999 Mar 12; 113(1-2):139-42. View abstract
  51. p53-dependent ceramide response to genotoxic stress. J Clin Invest. 1998 Jul 15; 102(2):329-39. View abstract